Cytokine storm: CRS, HLH, sepsis and severe COVID-19
- Topic
In a cytokine storm the immune system releases so many inflammatory signals that the response itself, not the trigger, causes shock and organ failure.
What it is
Cytokine storm is a life-threatening state of uncontrolled, systemic release of inflammatory cytokines such as IL-6, IL-1, TNF and IFN-γ. It shows as high fever, low blood pressure, capillary leak, cytopenias and multiorgan dysfunction. It occurs after CAR-T and T-cell-engaging therapies (cytokine release syndrome), in haemophagocytic lymphohistiocytosis, in severe infections including sepsis and COVID-19, and with superantigens. Treatment targets both the trigger and the dominant cytokine.
Key facts
- Ferritin rises very high in HLH and macrophage activation syndrome, higher than in most other inflammatory states.
- Soluble CD25 (IL-2 receptor α) is a marker of T-cell activation used in HLH work-up.
- Corticosteroids broadly suppress cytokine production but increase infection risk.
Step by step
- A trigger activates many cells at once: CAR-T or bispecific-engaged T cells, a virus, a superantigen, or killer cells that cannot finish their job.
- Activated T and NK cells release IFN-γ; macrophages respond with IL-6, IL-1 and TNF.
- These cytokines activate yet more macrophages and T cells: the loop feeds itself.
- Endothelium is activated and leaky: fever, hypotension, oedema and hypoxaemia.
- Macrophages engulf blood cells and the liver is injured: cytopenias, very high ferritin, low fibrinogen.
- Without treatment the result is multiorgan failure; blocking the dominant cytokine and removing the trigger breaks the loop.
Main settings of cytokine storm
| Setting | Trigger | Dominant mediators | Clues | Targeted approach |
|---|---|---|---|---|
| Cytokine release syndrome | CAR-T cells, bispecific T-cell engagers | IL-6, IFN-γ | Fever and hypotension days after infusion; may come with neurotoxicity | Tocilizumab, glucocorticoids |
| Haemophagocytic lymphohistiocytosis (HLH) | Inherited cytotoxicity defects; EBV, cancer, autoimmune disease | IFN-γ, IL-18 | Fever, splenomegaly, cytopenias, very high ferritin, low fibrinogen | Etoposide-based therapy, anti-IFN-γ, transplant for genetic forms |
| Macrophage activation syndrome | Still disease, systemic juvenile arthritis, lupus | IL-1, IL-18, IFN-γ | Falling ESR with rising ferritin in a known rheumatic patient | IL-1 blockade, glucocorticoids |
| Sepsis | Bacterial infection | TNF, IL-1, IL-6 | Organ dysfunction from infection; later immune paralysis | Antibiotics and source control; supportive care |
| Severe COVID-19 | SARS-CoV-2 | IL-6, IL-1, type I interferon imbalance | Hypoxaemia, high CRP and D-dimer, lymphopenia | Dexamethasone, tocilizumab or JAK inhibitor |
| Toxic shock syndrome | Staphylococcal or streptococcal superantigens | IL-2, TNF, IFN-γ from many T cells | Fever, rash, desquamation, shock | Remove source, antibiotics, supportive care |
Clinical notes
- Cytokine release syndrome is graded by fever, hypotension and oxygen needs; neurotoxicity (ICANS) is assessed separately.
- In a febrile patient with cytopenias and splenomegaly, very high ferritin should prompt consideration of HLH.
- Dexamethasone reduced mortality in hospitalised COVID-19 patients who needed oxygen.
Common traps
- Cytokine release syndrome after CAR-T means the therapy failed: CRS reflects T-cell activation and often accompanies a working therapy.
- Tocilizumab blocks IL-6 itself: it blocks the IL-6 receptor, so serum IL-6 can rise after it is given.
- A falling ESR in a sick rheumatic patient means improvement: in macrophage activation syndrome fibrinogen is consumed, so ESR falls while ferritin soars.
- HLH is always inherited: secondary HLH from EBV, cancer or autoimmune disease is more common in adults than the familial form.
- Glucocorticoids are harmless add-ons in every storm: they help in CRS and severe COVID-19 but increase infection risk, so sepsis care relies on source control.
Test yourself
Think of the answer, then tap the question to see it.
Five days after CAR-T infusion a patient has fever and hypotension. Which cytokine pathway is targeted first, and how?
IL-6, with tocilizumab blocking the IL-6 receptor; glucocorticoids are added for severe or neurologic toxicity.
A febrile patient has splenomegaly, pancytopenia, very high ferritin and low fibrinogen. What should you suspect and why the fibrinogen?
HLH: activated macrophages and liver injury consume and fail to make fibrinogen, while IFN-γ-driven macrophages raise ferritin.
Why does toxic shock syndrome cause a storm without any prior immunity?
Superantigens bind MHC class II and the TCR Vβ outside the antigen groove, activating a large fraction of all T cells at once.
Elsewhere in DurgiPedia
- Histiocytic disorders: HLH and Langerhans cell histiocytosis
- Systemic effects of inflammation: fever, acute-phase proteins, leukocytosis, sepsis
Connections
In Pharmacology3
Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.
Sources: CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers (National Cancer Institute (NIH), 2024); Familial hemophagocytic lymphohistiocytosis (MedlinePlus Genetics, US National Library of Medicine, 2024); COVID-19 (Coronavirus Disease 2019) (MedlinePlus, US National Library of Medicine, 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
